AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04179461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asthma Controller Medication
Description: Study participants asthma controller medication may be increased based off of their asthma control and the recommendation of the personalized plan.
Study NCT03100838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine 60 MG Extended Release Oral Tablet
Description: Reference Drug (Brand)
Study NCT03125642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AraC
Description: BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2
Study NCT03125642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: BEAM: 140 mg/m\^2 IV over 20 minutes on Day -1
Study NCT03125642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplantation
Description: All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.
Study NCT03125642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is >2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3
Study NCT03125642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \| CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6
Study NCT03125642 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: CY/TBI: 165 cGy bid on Day -4, -3, -2, -1
Study NCT02556086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study NCT02556086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Study NCT04172831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Study NCT04172831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SL Tablet
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Study NCT04210973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anyu Peibo
Description: Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
Study NCT04210973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule, twice per day, oral after breakfast and supper
Study NCT03662022 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rifampicin
Description: Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.
Study NCT03662022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.
Study NCT04544111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: 150 mg twice daily (OR at dose the patient previously tolerated)
Study NCT04544111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: 400mg IV every 4 weeks
Study NCT04581629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encaleret
Description: Tablets administered orally
Study NCT01178255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: homeopathic q-potencies
Description: individualised homeopathic medicines
Study NCT01178255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study NCT01178255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: homeopathic case history taking type I
Description: one special homeopathic technique for case history taking
Study NCT01178255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: homeopathic case history type II
Description: another type of homeopathic case history taking
Study NCT04483687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets administered orally once daily
Study NCT04483687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match Filgotinib
Description: Tablets administered orally once daily
Study NCT04483687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Match Filgotinib
Description: Tablets administered orally once daily
Study NCT00531674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified milk-based beverage
Description: Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
Study NCT00531674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sprinkles
Description: Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
Study NCT00531674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tablets
Description: Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
Study NCT00531674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified milk-based pap
Description: Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for children.
Study NCT00531674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Syrup
Description: Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
Study NCT01879527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride hydrochlorothiazide
Description: Blinding will be done by over-encapsulating amiloride HCT tablets and providing corresponding placebo capsules.Patients will be provided with capsules (size 00) containing one tablet of study medication (Amilostad HCT 5/50mg tablet or placebo) and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication. This maintenance dose will not be changed throughout the remaining study period. Placebo will be administered in the exact same manner.
Study NCT01879527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: containing placebo
Study NCT02812303 — intervention group
Intervention type: OTHER
Intervention: Centralized support for population health management activities
Study NCT02278471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)
Study NCT04997590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood mononuclear cells
Description: injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 2 week for a total of 3 times.
Study NCT04997590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Staphylococcal Enterotoxin C
Description: injection of staphylococcal enterotoxin C was performed once every 2 week for a total of 3 times.
Study NCT00640835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone Film Strip
Description: Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by sublingual route
Study NCT00640835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone Film Strip
Description: Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by buccal route
Study NCT03100838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine 60 MG Extended Release Oral Tablet
Description: Test Drug (Generic)
Study NCT03100838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine 60 MG Extended Release Oral Tablet
Description: Test Drug (Generic)
Study NCT03100838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole/sodium bicarbonate
Description: Proton Pump Inhibitor/Antacid for drug-drug interaction
Study NCT03100838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPill (TM)
Description: Gastric pH measurement using SmartPill (TM) Technology
Study NCT02426450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: RFA:~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).
Study NCT02426450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 4 weeks after RFA; Drug: Oxaliplatin Day 1: Oxaliplatin 85mg/m² 2h IV infusion. Repeated every 2 weeks
Study NCT02426450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil/Leucovorin
Description: 4 weeks after RFA; Drug: 5-Fluorouracil/Leucovorin Day 1, after Oxaliplatin 85mg/m² 2h IV infusion: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks
Study NCT00889486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-102
Study NCT00889486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00889486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03993145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based lifestyle intervention
Description: Lifestyle intervention program including educational modules on diet and physical activity with visual and audio. Phone conversation with the clinical dietician at week 1, week 3, week 6, week 12 and month 6 (completion of the study).
Study NCT01490190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)
Description: Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
Study NCT02757703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
Study NCT02757703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terlipressin
Description: A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
Study NCT02757703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.
Study NCT02757703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pantoprazole
Description: Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.
Study NCT02757703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic variceal ligation
Description: Two experienced endoscopists performed emergent EVL for the enrolled patients with acute EVB. Pneumoactive ligation device (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) and endoscopes (GIF XQ260; Olympus Co. Ltd, Tokyo, Japan) were applied. The targeted varix was suctioned and entrapped by a cap on endoscope. Ligation was aimed at active bleeding sites, red color spots or white nipple signs during the procedure.
Study NCT02757703 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopic variceal ligation
Description: Two experienced endoscopists performed emergent EVL for the enrolled patients with acute EVB. Pneumoactive ligation device (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) and endoscopes (GIF XQ260; Olympus Co. Ltd, Tokyo, Japan) were applied. The targeted varix was suctioned and entrapped by a cap on endoscope. Ligation was aimed at active bleeding sites, red color spots or white nipple signs during the procedure.
Study NCT01337427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017
Description: BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
Study NCT01337427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB017
Description: BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
Study NCT03431558 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: bLF (Bovine lactoferrin)
Description: BLF administration in two different strengths (150 \& 300mg) will be given on the third day of life with a single daily dose mixed with milk for 1 month.
Study NCT03100838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartPill (TM)
Description: Gastric pH measurement using SmartPill (TM) Technology
Study NCT01233102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conserved Therapy
Description: Conserved Therapy
Study NCT01233102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion or Intravenous infusion
Description: Patients with liver cirrhosis will be randomly divided into three groups. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group. The catheter will be inserted to proper hepatic artery. After the catheter placement confirmed by angiography, umbilical cord MSCs will be infused slowly in 20-30 minutes. Umbilical cord MSCs will be infused intravenously slowly for 30-60 minutes in the intravenous infusion group. The control group will receive conserved therapy.
Study NCT03431558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucon-D 99.4% (Placebo)
Description: This group will be given 100mg Glucon-D (99.4% glucose) placebo which will be similar in shape, color to the bLF.
Study NCT01024855 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)
Description: multi-purpose lens care solution
Study NCT01024855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)
Description: multi-purpose lens care solution
Study NCT01782937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827
Description: 140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)
Study NCT00253838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration HA stem
Description: The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating to be applied to the entire length of the stem.
Study NCT00253838 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Solution stem
Description: The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
Study NCT00003953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each 2 week course.
Study NCT00003953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMF regimen
Description: Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses
Study NCT00003953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel IV over 1 hour on days 43, 57, and 71.
Study NCT00003953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Doxorubicin IV on days 1, 15, and 29.
Study NCT00003953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Patients with positive estrogen or progesterone receptors receive oral tamoxifen daily for 5 years.
Study NCT00003953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Stratum III:may receive high dose chemotherapy with stem cell support
Study NCT00003953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical procedure
Description: Fourteen to 21 days following preoperative chemotherapy, patients undergo a radical, modified radical, or breast sparing surgery plus axillary lymph node dissection.
Study NCT00003953 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiotherapy is administered 5 days a week for 5.5 weeks.
Study NCT00743951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 Patient decision aid
Description: Patients will receive:~i)patient education booklet ii) a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form is an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referral to the surgeon with a standardized report of their clinical findings plus decisional data (knowledge, values, preference).
Study NCT00743951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Usual care
Description: Patient will be given i) education booklet from local hospital which is a standardized teaching booklet given to all patients describing preparation for surgery, recovery after surgery, discharge plans.~ii) Referral to the surgeon with a standardized report of their clinical findings.
Study NCT00743951 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 Usual care
Description: Patient will be given i) education booklet from local hospital which is a standardized teaching booklet given to all patients describing preparation for surgery, recovery after surgery, discharge plans.~ii) Referral to the surgeon with a standardized report of their clinical findings.
Study NCT03145987 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitis vinifera extract
Study NCT03145987 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00803816 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: everolimus
Description: everolimus 1.0 - 2.5mg oral daily dosage
Study NCT02043847 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Subjects in this trial will receive total marrow irradiation 3Gy per day for up to four days and as little as one day
Study NCT02043847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
Study NCT02043847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm\^3 over period of 3 days.
Study NCT02043847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous transplant
Description: Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
Study NCT02043847 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Subjects in this trial will receive total marrow irradiation 6Gy per day for up to four days and as little as one day
Study NCT02043847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm\^3 over period of 3 days
Study NCT02043847 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Subjects in this trial will receive total marrow irradiation 9Gy per day for up to four days and as little as one day
Study NCT03289364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penguin Cold Caps
Description: Patients will wear Penguin Cold Cap scalp cooling device prior to each chemotherapy administration, during administration, and for four hours following administration.
Study NCT03247803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air-Q® SP
Description: air-Q SP placement for airway maintenance,